NCT00555009 - Treatment Of Adult Growth Hormone Deficiency After Traumatic Brain Injury | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions

Brain InjuriesGrowth Hormone Deficiency

Interventions

DRUG

Genotropin

Subcutaneous injection, starting dose 0.2mg/day for males and 0.3mg/day for female with dose titration at 0.1mg to 0.2 mg increments in accordance to IGF-1 results for a total duration of 36 weeks.

DRUG

Placebo

Subcutaneous injection, with dummy dose titration for a total duration of 36 weeks.

Trial Locations (9)

41013

Pfizer Investigational Site, Seville

44100

Pfizer Investigational Site, Ferrara

75651

Pfizer Investigational Site, Paris

94010

Pfizer Investigational Site, Créteil

00168

Pfizer Investigational Site, Roma

3015 GD

Pfizer Investigational Site, Rotterdam

413 45

Pfizer Investigational Site, Gothenburg

171 76

Pfizer Investigational Site, Stockholm

M6 8HD

Pfizer Investigational Site, Salford